Abstract | BACKGROUND/AIM: PATIENTS AND METHODS:
Renal cell carcinoma patients who were treated from October 2007 to December 2018 at our Institution were retrospectively analyzed. RESULTS: Of 462 patients, the number of patients with and without hypertension was 234 (including 227 treated with anti-hypertensive agents) and 228, respectively. The tumor size was significantly smaller in the hypertension group than in the non- hypertension group (median 32 and 45 mm, respectively, p=0.010). The 5-year cancer-specific and metastasis-free survival in the hypertension group were significantly better than those in the non- hypertension group (93.6% and 80.4%, and 84.6% and 73.0%, respectively, p=0.021 and p=0.017). Propensity score matching revealed significantly better metastatic-free survival in the hypertension group than the non- hypertension group (p=0.022). CONCLUSION:
|
Authors | Tomoyuki Makino, Kouji Izumi, Hiroaki Iwamoto, Suguru Kadomoto, Renato Naito, Hiroshi Yaegashi, Kazuyoshi Shigehara, Yoshifumi Kadono, Atsushi Mizokami |
Journal | Anticancer research
(Anticancer Res)
Vol. 40
Issue 7
Pg. 4087-4093
(Jul 2020)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 32620657
(Publication Type: Journal Article)
|
Copyright | Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antihypertensive Agents
(therapeutic use)
- Carcinoma, Renal Cell
(epidemiology, pathology)
- Disease Progression
- Female
- Humans
- Hypertension
(drug therapy, epidemiology)
- Kidney Neoplasms
(epidemiology, pathology)
- Male
- Middle Aged
- Neoplasm Staging
- Prognosis
- Retrospective Studies
- Risk Factors
- Tumor Burden
- Young Adult
|